OJOG  Vol.4 No.8 , June 2014
Expression Analysis of p53, Ki-67 and bcl-2 in Pre-Malignant Lesions of the Cervix

Objectives: The present study has tried to analyze the individual and combined expression of the three markers—p53, Ki-67 and bel-2-in HPV associated pre-malignant lesions of the cervix. Methods: Thirty-four cases of high-grade lesions, 21 low-grade cases and 18 normal cases were histologically assessed. HPV-DNA presence and the viral types were determined through PCR and RFLP, respectively. Marker expression was performed by immuno-histochemistry.Results: With regards to viral types, HPV with high oncogenic potential represented the majority, with just one case reporting the low oncogenic potential for viral infection (HPV 6). HPV was the most frequent and could be associated with the high-grade lesion group, however, no significant associations were found between the viral ones and the marker expression. When the expression location, beyond the basal layer, was taken into account, the three markers proved to be good indicators of the lesion grade. The markers’ combined expression: p53(-), Ki-67(+), bcl-2(-) and p53(-), Ki-67(+), bcl-2(-) was statistically significant when associated with the lesion grade.Conclusions: The results suggest that the p53, Ki-67 and bel-2 markers can contribute to differentiate the lesion grades, whether in its isolate form or in combined form.

Cite this paper
Godoy, A. , Bazzo, K. , Moura, L. and Serafini, E. (2014) Expression Analysis of p53, Ki-67 and bcl-2 in Pre-Malignant Lesions of the Cervix. Open Journal of Obstetrics and Gynecology, 4, 462-469. doi: 10.4236/ojog.2014.48067.
[1]   World Health Organization (2008) International Agency for Research on Cancer. Globocan.

[2]   Instituto Nacional do Cancer—INCA (2014) Cancer de Colo do útero. http://www.inca.igov.br

[3]   Kitahara, S., Chan, R.C., Nichols, W.S. and Silva, E.G. (2012) Deceiving High-Grade Cervical Dysplasias Identified as Human Papillomavirus Non-16 and Non-18 Types by Invader Human Papillomavirus Assays. Annals of Diagnostic Pathology, 16, 100-106.

[4]   Marur, S., D’Souza, G., Westra, W.H. and Forastiere, A.A. (2010) HPV-Associated Head and Neck Cancer: A Virus-Related Cancer Epidemic. The Lancet Oncology, 11, 781-789.

[5]   Park, K.J. (2011) Neoplastic Lesions of the Cervix. Surgical Pathology Clinics, 4, 17-86.

[6]   Thomas, M.K., Pitot, H.C., Liem, A. and Lambert, P.F. (2011) Dominant Role of HPV16 E7 in Anal Carcinogenesis. Virology, 421, 114-118. http://dx.doi.org/10.1016/j.virol.2011.09.018

[7]   Vidal, L. and Gillison, M.L. (2008) Human Papillomavirus in HNSCC: Recognition of a Distinct Disease Type. Hematology/Oncology Clinics of North America, 22, 1125-1142.

[8]   Priebe, A.M. (2013) 2012 Cervical Cancer Screening Guidelines and the Future Role of HPV Testing. Clinical Obstetrics and Gynecology, 56, 44-50. http://dx.doi.org/10.1097/GRF.0b013e3182836b6a

[9]   von Knebel Doeberitz, M. (2002) New Markers for Cervical Dysplasia to Visualise the Genomic Chaos Created by Aberrant Oncogenic Papillomavirus Infections. European Journal of Cancer, 38, 2229-2242. http://dx.doi.org/10.1016/S0959-8049(02)00462-8

[10]   Carrilho, C., Gouveia, P., Cantel, M., Alberto, M., Buane, L. and David, L. (2003) Characterization of Human Papillomavirus Infection, p53 and Ki-67 Expression in Cervix Cancer of Mozambican Women. Pathology—Research and Practice, 199, 303-311. http://dx.doi.org/10.1078/0344-0338-00422

[11]   Katiyar, S., Hedau, S., Jain, N., Kar, P., Khuroo, M.S., Mohanta, J., Das, B.C., et al. (2005) p53 Gene Mutation and Human Papillomavirus (HPV) Infection in Esophageal Carcinoma from Three Different Endemic Geographic Regions of India. Cancer Letters, 218, 69-79.

[12]   Levine, A.J. (1997) p53 the Cellular Gatekeeper for Growth and Devision. Cell, 88, 323. http://dx.doi.org/10.1016/S0092-8674(00)81871-1

[13]   Cotran, R.S., Kumar, V. and Collins, T. (1999) Patologia Básica. 5th Edition, Guanabara Koogan, Rio de Janeiro.

[14]   Wang, Z., Sturgis, E.M., Zhang, Y., Huang, Z., Zhou, Q., Wei, Q. and Li, G. (2012) Combined p53-Related Genetic Variants Together with HPV Infection Increase Oral Cancer Risk. International Journal of Cancer, 131, E251-E258. http://dx.doi.org/10.1002/ijc.27335

[15]   Habbous, S., Pang, V., Eng, L., Xu, W., Kurtz, G., Liu, F.-F., Liu, G., et al. (2012) p53 Arg72Pro Polymorphism, HPV Status and Initiation, Progression, and Development of Cervical Cancer: A Systematic Review and Meta-Analysis. Clinical Cancer Research, 18, 6407-6415.

[16]   Gross, G.E. and Barrasso, R. (1999) Infeccao por Papilomavírus Humano: Atlas Clínico de HPV. Artes Médicas, Porto Alegre.

[17]   Storey, A., Thomas, M., Kalita, Harwood, C., Gardiol, D., Mantovani, F., et al. (1998) Role of a p53 Polymorphism in the Development of Human Papillomavirus Associated Cancer. Nature, 393, 229-234. http://dx.doi.org/10.1038/30400

[18]   Zehbe, I., Voglino, G., Wilander, E., Genta, F. and Tommasino, M. (1999) Codon 72 Polymorphism of p53 and It Is Association with Cervical Cancer. Lancet, 354, 218-219.

[19]   Dokianakis, D.N. and Spandidos, D.A. (2000) p53 Codon72 Polymorphism as a Risk Factor in the Development of HPV: Associated Cervical Cancer. Molecular Cell Biology Research Communications, 3, 111-114. http://dx.doi.org/10.1006/mcbr.2000.0196

[20]   Makni, H., Franco,E.L., Kaiano, J., Villa, L.L., Labrecque, S., Dudley, R., et al.. (2000) p53 Polymorphism in Codon 72 and Risk of Human Papillomavirus—Induced Cervical Cancer: Effect of Interlaboratory Variation. International Journal of Cancer, 87, 528-533.

[21]   Andersson, S., Rylander, E., Strand, A., Salsstrom, J. and Willander, E. (2001) The Significance of p 53 Codon 72 Polymorphism for the Development of Cervical Adenocarcinomas. British Journal of Cancer, 85, 1153-1156. http://dx.doi.org/10.1054/bjoc.2001.2085

[22]   Klug, S.J., Wilmotte, R., Santos, C., Almonte, M., Herrero, R., Guerrero, I., et al. (2001) Tp53 Polymorphism, HPV Infections, and Risk of Cervical Cancer. Cancer Epidemiology, Biomarkers and Prevention, 10, 1009-1012.

[23]   Zehbe, I., Voglino, G., Wilander, E., Delius, Marongiu, A., Edler, L., et al. (2001) p53 Codon 72 Polymorphism and Various Human Papillomavirus 16 E6 Genotypes Are Risk Factors for Cervical Cancer Development. Cancer Research, 61, 608-611.

[24]   Saranath, D., Khan, Z., Tandle, A.T., Dedhia, P., Sharma, B., Contractor, R., et al. (2002) HPV 16/18 Prevalence in Cervical Lesions/Cancer and p53 Genotypes in Cervical Cancer Patients from India. Gynecologic Oncology, 86, 157-162. http://dx.doi.org/10.1006/gyno.2002.6735

[25]   Ojeda, J.M., Ampuero, S., Rojas, P., Prado, R., Allende, J.E., Barton, S.A., et al. (2003) p53 Codon 72 Polymorphism and Risk of Cervical Cancer. Biological Research, 36, 279-283.

[26]   Silva-Filho, A.L., Traiman, P., Triginelli, S.A., Reis, F.M., Pedrosa, M.S., Miranda, D., Cunha-Melo, J.R., et al. (2004) Expression of p53, Ki-67, and CD31 in the Vaginal Margins of Radical Hysterectomy in Patients with Stage IB Carcinoma of the Cervix. Gynecologic Oncology, 95, 646-654.

[27]   Ungureanu, C., Teleman, S., Socolov, D., Anton, G. and Mihailovici, M. (2010) Evaluation of p16INK4a and Ki-67 Proteins Expression in Cervical Intraepithelial Neoplasia and Their Correlation with HPV-HR Infection. Revista Medico-Chirurgicala a Societatii de Medici si Naturalisti din Iasi, 114, 823.

[28]   D’Angelo, E., Espinosa, I., Ali, R., Gilks, C.B., Rijn, M.V.D., Lee, C.-H. and Prat, J. (2011) Uterine Leiomyosarcomas: Tumor Size, Mitotic Index, and Biomarkers Ki67, and bcl-2 Identify Two Groups with Different Prognosis. Gynecologic Oncology, 121, 328-333.

[29]   Subapriya, R., Kumaraguruparan, R. and Nagini, S. (2006) Expression of PCNA, Cytokeratin, bcl-2 and p53 during Chemoprevention of Hamster Buccal Pouch Carcinogenesis by Ethanolic Neem (Azadirachta indica) Leaf Extract. Clinical Biochemistry, 39, 1080-1087.

[30]   Zyada, M.M., Grawish, M.E. and Elsabaa, H.M. (2009) Predictive Value of Cyclooxygenase 2 and bcl-2 for Cervical Lymph Node Metastasis in Mucoepidermoid Carcinoma. Annals of Diagnostic Pathology, 13, 313-321. http://dx.doi.org/10.1016/j.anndiagpath.2009.06.003

[31]   Banerjee, S.K., Makdisi, W.F., Weston, A.P., Mitchell, S.M. and Campbell, D.R. (1995) Microwave-Based DNA Extraction from Paraffin-Embedded Tissue for PCR Amplification. Biotechniques, 18, 768-770.

[32]   Bernard, H.U., Manos S.Y., Ong M.M., Villa C.K., Delius L.L., et al. (1994) Identification and Assessment of Known And Novel Human Papillomaviruses by Polymerase Chain Reaction Amplification, Restriction Fragment Length Polymorphisms, Nucleotide Sequence, and Phylogenetic Algorithms. Journal of Infectious Diseases, 170, 1077-1085.

[33]   Carrilho, C., Gouveia, P., Cantel, M., Alberto, M., Buane, L. and David, L. (2003) Characterization of Human Papillomavirus Infection, p53 and Ki-67 Expression in Cervix Cancer of Mozambican Women. Pathology-Research and Practice, 199, 303-311. http://dx.doi.org/10.1078/0344-0338-00422

[34]   Kedzia, W., Schimidt, M., Frankowski, A. and Spaczynski, M. (2002) Immmunohistochemical Assay of p53, Cyclin D1, c-erbB2, EGFr and Ki-67 Proteins in HPV-Positive and HPV Negative Cervical Cancers. Folia Histochemica et Cytobiologia, 40, 37-41.

[35]   Barea, J.A., Pardini, M.I.M.C. and Gushiken, T. (2004) Extra??o de DNA de Materiais de Arquivo e Fontes Escassas: Revis?o e Apontamentos Sobre as Possíveis Aplica??es. NewsLab, 63, 96-108.

[36]   Zehbe, I. and Wilander, E. (1997) Human Papillomavirus Infection and Invasive Cervical Neoplasia: A Study of Prevalence and Morphology. Journal of Pathology, 181, 270-275.

[37]   Gadducci, A., Guerrieri, M.E. and Greco, C. (2012) Tissue Biomarkers as Prognostic Variables of Cervical Cancer. Critical Reviews in Oncology/Hematology, 86, 104-129.

[38]   Tosun, G., Sendag, F., Zeybek, B., Cosan, T. M., Guven, C., Zekiogly, O. and Bilgin, O. (2010) Immunohisto-Chemical Expressions of p16 and p53 Proteins in Cervical Intraepithelial Neoplasia and in Benign Cervical Tissue. European Journal of Obstetrics and Gynecology, 31, 627-631.

[39]   Kurvinen, K., Syrjanen, K. and Syrjanen S. (1996) p53 and bcl-2 Proteins as Prognostic Markers in Human Papillomavirus: Associated Cervical Lesions. Journal of Clinical Oncology, 14, 2120-2130.

[40]   Martin, C.M. and O’Leary, J.J. (2011) Histology of Cervical Intraepithelial Neoplasia and the Role of Biomarkers. Best Practice & Research Clinical Obstetrics & Gynaecology, 25, 605-615.

[41]   Pavlakis, K., Vrekoussis, T., Tsipoura, A., Tsenga, A., Arapantoni-Dadioti, P., Gavresea, T., Barbounis, V., et al. (2012) Her2 Negative Luminal Breast Carcinoma and Ki-67 Evaluation. The Breast, 21, 529-533. http://dx.doi.org/10.1016/j.breast.2012.04.004

[42]   Walts, A.E. and Bose, S. (2009) p16, Ki-67, and BD ProExTMC Immunostaining: A Practical Approach for Diagnosis of Cervical Intraepithelial Neoplasia. Human Pathology, 40, 957-964.

[43]   Wang, W.-C., Wu, T.-T., Chandan, V.S., Lohse, C.M. and Zhang, L. (2011) Ki-67 and ProExC Are Useful Immunohistochemical Markers in Esophageal Squamous Intraepithelial Neoplasia. Human Pathology, 42, 1430-1437. http://dx.doi.org/10.1016/j.humpath.2010.12.009

[44]   Keating, J.T., Cviko, A., Riethford, S., Riethdord, L., Quade, B., Sun, D., et al. (2001) Ki-67, Cyclin E, and p16INK4 Are Complimentary Surrogate Biomarkers for Human Papilloma Virus: Related Cervical Neoplasia. American Journal of Surgical Pathology, 25, 884-891.

[45]   Kurvinen, K., Syrjanen, K. and Syrjanen S. (1996) p53 and bcl-2 Proteins as Prognostic Markers in Human Papillomavirus: Associated Cervical Lesions. Journal of Clinical Oncology, 14, 2120-2130.

[46]   Hockenbery, D.M., Zutter, M.W., Naham, M. and Korsmeyer, S.J. (1991) bcl-2 Protein Is Topographically Restricted in Tissues Characterized by Apoptotic Cell Death. Proceedings of the National Academy of Sciences of the United States of America, 88, 6961-6965.

[47]   Queiroz, C., Silva, T.C., Alves, V.A., Villa, L.L., Costa, M.C., Travassos, A.G., de Freitas, L.A.R., et al. (2006) Comparative Study of the Expression of Cellular Cycle Proteins in Cervical Intraepithelial Lesions. Pathology-Research and Practice, 202, 731-737.

[48]   Eaton, S., Wiktor, P., Thirstrup, D., Lake, D. and Nagaraj, V.J. (2011) Efficacy of TRAIL Treatment against HPV16 Infected Cervical Cancer Cells Undergoing Senescence Following siRNA Knockdown of E6/E7 Genes. Biochemical and Biophysical Research Communications, 405, 1-6.

[49]   Guo, M., Dhillon, J., Khanna, A., Katz, R., Gong, Y. and Staerkel, G. (2012) Cervista HPV HR and HPV16/18 Assays in Head and Neck FNA Specimens, a Valid Option of HPV Testing, Compared with HPV in Situ Hybridization/p16 Immunostaining Assays in Tissue Specimens from Patients with Oropharyngeal Carcinoma. Journal of the American Society of Cytopathology, 1, S71-S71.